Remiges Ventures

Remiges Ventures is a Massachusetts-based venture capital firm that specializes in early-stage investments in the pharmaceutical industry, particularly in drug discovery and development. The firm targets opportunities within the Japanese academia and pharmaceutical sectors, aiming to support innovative companies that are advancing healthcare solutions. By focusing on these specific markets, Remiges Ventures seeks to foster growth and development in the biotechnology landscape, leveraging its expertise to identify and nurture promising ventures in both the United States and Japan.

Matt Green

Investment Manager

Taro Inaba

Managing Partner

Yuki Kamiya

Investment Manager

Taka Koda

Partner

Kyoko Matsumoto

Senior Associate

Kazuhiko Nonomura

Principal

Walter Olesiak

Operating Partner

Takaaki Tobaru

Partner

Takuma Tsuzuku

Investment Manager

13 past transactions

LUCA Science

Series B in 2022
Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Capacity Bio

Seed Round in 2022
Capacity Bio is a therapeutics company that is focused on mitophagy. Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondrial quality control in disease.

Glycomine

Series B in 2021
Glycomine, Inc. is a biotechnology company based in San Carlos, California, established in 2014. The company specializes in developing nanomedicines aimed at treating rare genetic disorders, particularly those related to protein and lipid glycosylation. These disorders often lead to significant health challenges for affected individuals, and Glycomine focuses on creating therapeutics for diseases that currently lack FDA-approved treatment options. With approximately 7,000 rare disorders identified worldwide, and a majority of them without viable therapies, Glycomine is positioned to address critical unmet medical needs in this niche area of healthcare.

Cyrano Therapeutics

Series A in 2020
Cyrano Therapeutics, Inc., founded in 2014 and headquartered in Washington, D.C., develops therapeutic solutions aimed at addressing taste and smell disorders. The company's primary offering is an intranasal product, CYR-001, which repurposes the approved molecule Theophylline to restore sensory function in patients experiencing chronic loss of taste and smell. In preliminary studies, the treatment demonstrated significant efficacy, with eight out of ten patients showing notable improvements within two weeks and no reported side effects. In addition to the therapy, Cyrano Therapeutics provides a diagnostic kit to assess and quantify the severity of sensory loss, which can assist healthcare providers, particularly otolaryngologists, in managing care for affected individuals, including cancer patients undergoing chemotherapy who may experience sensory changes.

LUCA Science

Series A in 2020
Luca Science Inc. specializes in creating a new treatment using mitochondria, which is bioenergy itself. It is based in Japan.

Tranquis Therapeutics

Series A in 2020
Tranquis Therapeutics, Inc., a biotechnology company, engages in developing immuno-therapeutics for neurodegenerative and aging-related diseases. Its TQS-168 is a therapeutic candidate that targets underlying myeloid immune cell dysfunction that is linked to a variety of nervous system disorders. Its solution is used to treat amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. The company was incorporated in 2016 and is based in San Mateo, California.

OMEICOS Therapeutics

Series C in 2018
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

ENB Therapeutics

Series A in 2018
ENB Therapeutics, LLC develops small molecule inhibitors to treat melanoma and other cancers. The product includes ENB-001 that restores the ability of T-cells to infiltrate tumors and inhibits metastasis. The company was incorporated in 2015 and is based in New York, New York.

KisoJi Biotechnology

Series A in 2018
KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers.

OMEICOS Therapeutics

Series B in 2017
OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

Mitoconix Bio

Series A in 2017
Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

InFlectis BioScience

Series A in 2016
InFlectis BioScience is a drug discovery company based in Nantes, France, established in 2013. The company specializes in developing small molecule drugs that target the unfolded protein response, aiming to address misfolded protein disorders linked to neurodegenerative and age-related diseases. By focusing on the cellular defense system against misfolded proteins, InFlectis BioScience seeks to modulate key proteins involved in maintaining endoplasmic reticulum (ER) proteostasis, which is essential for cellular function and survival. The company’s innovative approach helps to safeguard cellular integrity by managing ER stress, a condition that arises when the folding capacity of the ER is compromised. Through its research and development efforts, InFlectis BioScience strives to advance preclinical-stage products that can enhance patient care while maximizing the commercial potential of its offerings.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.